Edition:
United States

Karyopharm Therapeutics Inc (KPTI.OQ)

KPTI.OQ on NASDAQ Stock Exchange Global Select Market

19.56USD
4:00pm EDT
Change (% chg)

$0.76 (+4.04%)
Prev Close
$18.80
Open
$18.85
Day's High
$19.65
Day's Low
$18.85
Volume
206,975
Avg. Vol
244,055
52-wk High
$20.38
52-wk Low
$8.00

Latest Key Developments (Source: Significant Developments)

Karyopharm Announces Positive Top-Line Data From Phase 2b STORM Study Evaluating Selinexor In Patients With Penta-Refractory Multiple Myeloma
Monday, 30 Apr 2018 04:05pm EDT 

April 30 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM ANNOUNCES POSITIVE TOP-LINE DATA FROM PHASE 2B STORM STUDY EVALUATING SELINEXOR IN PATIENTS WITH PENTA-REFRACTORY MULTIPLE MYELOMA.KARYOPHARM THERAPEUTICS INC - SELINEXOR CONTINUES TO DEMONSTRATE A PREDICTABLE AND MANAGEABLE TOLERABILITY PROFILE.KARYOPHARM THERAPEUTICS INC - COMPANY PLANS TO SUBMIT A NEW DRUG APPLICATION TO FDA IN SECOND HALF OF 2018.KARYOPHARM THERAPEUTICS INC - REGARDING STORM STUDY'S PRIMARY OBJECTIVE, ORAL SELINEXOR ACHIEVED A 25.4% OVERALL RESPONSE RATE.KARYOPHARM THERAPEUTICS INC - PLANS TO SUBMIT A MARKETING AUTHORIZATION APPLICATION TO EUROPEAN MEDICINES AGENCY IN EARLY 2019.KARYOPHARM THERAPEUTICS INC - EXPECTING TO COMPLETE ENROLLMENT IN BOSTON STUDY BY END OF 2018, WITH TOP-LINE DATA ANTICIPATED IN 2019.  Full Article

Karyopharm Therapeutics Reports Q4 Loss Per Share Of $0.80
Thursday, 15 Mar 2018 07:00am EDT 

March 15 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS.Q4 LOSS PER SHARE $0.80.Q4 EARNINGS PER SHARE VIEW $-0.65 -- THOMSON REUTERS I/B/E/S.PHASE 2B STORM STUDY EVALUATING SELINEXOR IN PATIENTS WITH PENTA-REFRACTORY MYELOMA REMAINS ON TRACK.TOP-LINE DATA FROM PHASE 2B STORM STUDY EXPECTED END OF APRIL 2018.KARYOPHARM - CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF DEC 31, 2017, INCLUDING RESTRICTED CASH, TOTALED $176.4 MILLION, VERSUS $175.5 MILLION AT DEC 31, 2016.EXPECTS EXISTING CASH, CASH EQUIVALENTS AND INVESTMENTS TO BE SUFFICIENT TO FUND OPERATIONS THROUGH AT LEAST Q1 2019.QTRLY LICENSE AND OTHER REVENUE $1.5 MILLION VERSUS $ 47,000.  Full Article

Karyopharm Announces Agreement For Biogen To Acquire KPT-350
Thursday, 25 Jan 2018 06:30am EST 

Jan 25 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM ANNOUNCES AGREEMENT FOR BIOGEN TO ACQUIRE KPT-350 FOR THE TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE CONDITIONS.KARYOPHARM THERAPEUTICS INC - DEAL VALUED AT UP TO $217 MILLION.KARYOPHARM THERAPEUTICS - ‍BIOGEN IS ACQUIRING KPT-350 AND OTHER ASSETS TARGETING CERTAIN NEUROLOGICAL CONDITIONS, INCLUDING ALS.KARYOPHARM - DEAL INCLUDES $10 MILLION UPFRONT PAYMENT TO KARYOPHARM, AND POTENTIAL $207 MILLION IN FUTURE MILESTONES, PLUS ROYALTIES.KARYOPHARM - CO ALSO ELIGIBLE TO GET TIERED ROYALTIES FROM BIOGEN THAT REACH LOW DOUBLE DIGITS BASED ON FUTURE NET SALES OF SOME PRODUCT CANDIDATES.  Full Article

Karyopharm Therapeutics Says Co May Issue & Sell Shares Of Stock
Friday, 1 Dec 2017 04:26pm EST 

Dec 1 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM THERAPEUTICS - CO MAY ISSUE & SELL SHARES OF STOCK, $0.0001 PAR VALUE PER SHARE, HAVING ADDITIONAL OFFERING PRICE OF UP TO $75 MILLION.KARYOPHARM THERAPEUTICS - ON DEC 1, CO ENTERED INTO AMENDMENT NO. 2 TO CONTROLLED EQUITY OFFERING SALES AGREEMENT, DATED DECEMBER 7, 2015 - SEC FILING.  Full Article

Point72 Asset Management L.P. reports 7.3 pct passive stake in Karyopharm Therapeutics Inc as of Nov. 3 - SEC filing‍​
Monday, 6 Nov 2017 04:32pm EST 

Nov 6 (Reuters) - Karyopharm Therapeutics Inc :Point72 Asset Management L.P. reports 7.3 percent passive stake in Karyopharm Therapeutics Inc as of November 3, 2017 - SEC filing‍​.  Full Article

Karyopharm Q3 loss per share $0.65
Thursday, 2 Nov 2017 07:00am EDT 

Nov 2 (Reuters) - Karyopharm Therapeutics Inc ::Karyopharm reports third quarter 2017 financial results and highlights recent progress.Q3 loss per share $0.65.Q3 earnings per share view $-0.65 -- Thomson Reuters I/B/E/S.Karyopharm Therapeutics Inc - ‍expect to report top-line results of phase 2b storm study by april 2018​.  Full Article

Karyopharm reports positive data from ongoing cancer drug study
Wednesday, 20 Sep 2017 07:00am EDT 

Sept 20 (Reuters) - Karyopharm Therapeutics Inc :Karyopharm announces successful outcome from phase 2 portion of phase 2/3 seal study evaluating selinexor in patients with previously treated advanced dedifferentiated liposarcoma.Karyopharm Therapeutics - ‍phase 3 portion of 2/3 seal​ study commenced; expanded to include North America, Europe, expected to enroll up to 222 patients.Karyopharm Therapeutics Inc - ‍top-line of data expected by end of 2019 for 2/3 seal study​.Karyopharm Therapeutics - ‍FDA has confirmed its acceptance of proposed phase 3 seal study design, including PFS primary endpoint.  Full Article

Karyopharm Therapeutics Q2 loss per share $0.64
Tuesday, 8 Aug 2017 07:00am EDT 

Aug 8 (Reuters) - Karyopharm Therapeutics Inc :Karyopharm reports second quarter 2017 financial results and highlights recent progress.Q2 loss per share $0.64.Q2 earnings per share view $-0.65 -- Thomson Reuters I/B/E/S.  Full Article

Karyopharm Q1 loss per share $0.71
Thursday, 4 May 2017 07:00am EDT 

May 4 (Reuters) - Karyopharm Therapeutics Inc ::Karyopharm reports first quarter 2017 financial results and highlights recent progress.Q1 loss per share $0.71.Q1 earnings per share view $-0.67 -- Thomson Reuters I/B/E/S.  Full Article

Karyopharm and Anivive Lifesciences sign exclusive global license agreement for Verdinexor for Animal Health Applications
Wednesday, 3 May 2017 04:05pm EDT 

May 3 (Reuters) - Karyopharm Therapeutics Inc :Karyopharm and Anivive Lifesciences sign exclusive global license agreement for Verdinexor for Animal Health Applications.Karyopharm Therapeutics Inc - Karyopharm to receive $1 million upfront payment.Karyopharm Therapeutics Inc - Karyopharm then eligible to receive up to $43.5 million in future milestones, plus royalties.  Full Article

BRIEF-Karyopharm Therapeutics Reports Q1 Loss Per Share Of $0.78

* KARYOPHARM REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS